Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eplerenone in Heart Failure with Preserved Ejection Fraction
NCT04078425Phase 1Unknown
- Sponsor
- Assiut University
- Start
- Mar 2020
- Primary completion
- Mar 2022
- Modality
- Orthosteric Ligands
01
Overview
Phase 1, randomised, open-label trial of eplerenone in heart failure with preserved ejection fraction (HFpEF) (2 arms), sponsored by Assiut University. Primary endpoint: Role of aldosterone antagonist in treatment of heart failure at 6 months. Status: unknown.
02
Drugs
eplerenone
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT04078425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04078425.